In a SURPASS-CVOT subgroup with heart failure, the combined outcome hit 18.2% on tirzepatide vs 21.5%, mostly from fewer deaths. Authors call it hypothesis generating.
Recap by typeshit. Full story at The American Journal of Managed Care.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A six-minute case video on a patient still above her goals after losing weight on Wegovy. Novo Nordisk funded the production, so treat it as sponsored education.
A TV health segment looks at how dentists are using a peptide to help patients' teeth. Light on specifics, so tap through for the details.
Loading…